Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
NiQuitin CQ
GlaxoSmithKline's UK launch of smoking cessation lozenges backed by £10 mil. (approximately $14.2 mil.) marketing campaign including £5 mil. ad campaign beginning in December, firm says. Mint-flavored lozenges contain either 2 mg or 4 mg nicotine polacrilex and launched in UK pharmacies in October. A one-week supply costs roughly $24.80. Launch could pave the way for eventual product introduction in U.S. Study finding lozenges lead to higher success rate than other nicotine-replacement therapies slated for publication in March Archives of Internal Medicine...
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
• By
Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.
• By
If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.